Green Alpha Advisors LLC Acquires Shares of 5,178 Twist Bioscience Corporation $TWST

Green Alpha Advisors LLC bought a new stake in Twist Bioscience Corporation (NASDAQ:TWST) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 5,178 shares of the company’s stock, valued at approximately $533,000.

Other large investors have also made changes to their positions in the company. Royal Bank of Canada boosted its position in Twist Bioscience by 11.8% in the first quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after buying an additional 4,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Twist Bioscience by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock worth $2,765,000 after buying an additional 3,181 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Twist Bioscience by 4.2% in the first quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock valued at $36,629,000 after acquiring an additional 37,577 shares during the last quarter. Intech Investment Management LLC raised its stake in shares of Twist Bioscience by 18.9% in the first quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock valued at $1,135,000 after acquiring an additional 4,591 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Twist Bioscience in the 2nd quarter worth approximately $737,000.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 291 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $87.32, for a total transaction of $25,410.12. Following the transaction, the senior vice president directly owned 120,414 shares in the company, valued at approximately $10,514,550.48. This represents a 0.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,399 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $94.33, for a total transaction of $226,297.67. Following the completion of the transaction, the chief financial officer directly owned 110,276 shares in the company, valued at $10,402,335.08. This trade represents a 2.13% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 151,529 shares of company stock worth $17,708,772 in the last ninety days. 3.08% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on TWST shares. Canaccord Genuity Group lifted their price objective on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Evercore cut Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 target price on the stock. in a report on Monday, July 6th. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Leerink Partners set a $110.00 price target on Twist Bioscience in a report on Thursday, July 16th. Finally, Barclays upped their price target on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and an average price target of $98.30.

Twist Bioscience Stock Up 6.8%

NASDAQ:TWST opened at $145.59 on Friday. The company has a market cap of $9.13 billion, a price-to-earnings ratio of -65.58 and a beta of 2.14. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The stock’s fifty day moving average price is $100.69 and its two-hundred day moving average price is $70.33. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $145.93.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The firm had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period last year, the business posted $0.33 earnings per share. On average, analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.